Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Net Product Sales and Gross Margin Performance
REGN logo

Regeneron Revenues Surge 19% to $3.6 Billion Driven by EYLEA HD and Dupixent Growth

REGN8-KFiling Date: 4/29/2026
Regeneron Pharmaceuticals, Inc.
Description

What this story covers

Regeneron's Q1 2026 results reveal a 19 percent revenue increase to 3 point 6 billion dollars, fueled by strong collaboration profits and new product uptake. Despite higher R&D spending and tax rates impacting EPS, the company maintains a robust clinical pipeline.

Story snapshot

CompanyRegeneron Pharmaceuticals, Inc.
TickerREGN
VariantStandard detailed
Duration5:32
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000872589-26-000014
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in